

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

A mixture of essential oils from three Cretan Aromatic Plants (thyme, Greek sage and Cretan dittany, CAPEo) inhibits SARS-CoV-2 proliferation: *in vitro* evidence and a Proof-of-Concept intervention study in mild ambulatory COVID-19-positive patients

Christos Lionis^{1,*}, Ioannis Karakasiliotis², Elena Petelos¹, Manolis Linardakis¹, Athanasios Diamantakis¹, Emmanouil Symvoulakis¹, Maria Panopoulou^{3,4}, Marilena Kampa⁵, Stergios A. Pirintsos^{6,7}, George Sourvinos⁸, Elias Castanas^{5,*}

1 Clinic of Social and Family Medicine, School of Medicine, University of Crete, Heraklion, Greece

2 Laboratory of Biology, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece

3 Laboratory of Clinical Microbiology, University General Hospital, Alexandroupolis, Greece

4 Laboratory of Microbiology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.

5 Laboratory of Experimental Endocrinology, School of Medicine, University of Crete, University of Crete, Heraklion, Greece

6 Department of Biology, School of Sciences and Technology, University of Crete, Heraklion, Greece

7 Botanical Garden, University of Crete, Rethymnon, Greece

8 Laboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion, Greece

* **Correspondence:** Christos Lionis (lionis@uoc.gr) or Elias Castanas (castanas@uoc.gr), University of Crete, School of Medicine, Voutes University Campus, 71013, Heraklion, Greece

30 **Abstract**

31 The need for therapeutic regimens for the non-critically ill patients of the COVID-19 pandemic remains
32 unmet. In this line, repurposing existing drugs, against known or predicted SARS-CoV-2 protein actions,
33 has been advanced, while natural products have also been tested. Previous work has shown that a Cretan
34 Aromatic Plant (*Thymbra capitata* (L.) Cav., *Salvia fruticosa* Mill. and *Origanum dictamnus* L.) essential oil
35 mixture (CAPEo) has a remarkable *in vitro* antiviral activity against Influenza A & B and Rhinovirus 14
36 strains, decreasing the symptoms of upper respiratory tract infections, while proven safe in experimental
37 animals and humans. Here, we tested CAPEo in VERO cells infected with SARS-CoV-2. We report that this
38 mixture, at similar concentrations as those previously reported, exhibits a remarkable antiviral activity.
39 Administration of 1 ml of a 1.5% CAPEo in olive oil, in a Proof-of-Concept intervention study in SARS-CoV-
40 2-positive, exhibiting mild COVID-19 symptoms, humans resulted in a significant amelioration of general
41 and local symptoms of the disease. We conclude that CAPEo may be a valuable addition for the prevention
42 and/or treatment of mild COVID-19 ambulatory patients, pending a confirmation through a prospective
43 randomized controlled trial in humans (NCT04705753).

44

45 **Keywords**

46 SARS-CoV-2, COVID-19, natural products, essential oils, therapeutic agent

47

48 Introduction

49 Since the outbreak of COVID-19 pandemics, in 2019, a previously unseen international effort has been
50 undertaken for the identification of the underlying cause (the SARS-CoV-2 virus) and the detailed analysis
51 of its genome (O'Leary and Ovsepien, 2020). An international effort is actually directed towards an
52 efficient therapy (Baum et al., 2020;Hansen et al., 2020;Weinreich et al., 2020), or the development of
53 efficient vaccines (Polack et al., 2020;Voysey et al., 2020). A number of established pharmaceutical
54 molecules and patients' plasma have been tested as drug candidates for the treatment of COVID-19, with
55 variable results (see (Bolarin et al., 2020;Wang et al., 2020a;Wang et al., 2020b) and references herein).
56 Among the multitude of products tested against COVID-19 disease, a number of natural products,
57 including herbal extracts, have also been assayed (critically reviewed in (Benarba and Pandiella, 2020) and
58 references herein), targeting mainly the viral proteases.

59 Recently, we have reported that a combination of three aromatic plants essential oil (CAPEo) (*Thymbra*
60 *capitata* (L.) Cav., *Origanum dictamnus* L., *Salvia fruticosa* Mill., (Pirintsos et al., 2020), and references
61 herein) is efficient against upper respiratory tract viral infections, in humans (Duijker et al.,
62 2015;Anastasaki et al., 2017). *In vitro* studies revealed the efficacy of CAPEo against Influenza A & B and
63 Human Rhinovirus 14, and reported an action through the inhibition of the nuclear translocation of viral
64 nucleoproteins (Tseliou et al., 2019), resulting in impaired viral protein transcription. Furthermore, we
65 have reported the safety of CAPEo, both in humans (administered in the form of soft gels, 1 ml/day of a
66 1.5% essential oil combination in extra virgin olive oil, (Duijker et al., 2015)) and in experimental animals
67 (Kalyvianaki et al., 2020). In the present study, we have assayed the efficiency of CAPEo mixture on the
68 proliferation of SARS-CoV-2 in VERO cells. We report a remarkable antiviral activity of CAPEo, at
69 concentrations compatible with those obtained after the recommended dose administration in humans.
70 Moreover, we performed a Proof-of-Concept intervention study in mild COVID-19-positive humans and
71 report that CAPEo can significantly ameliorate the general and local symptoms of the disease. We suggest
72 that CAPEo, pending additional confirmation of results through a prospective randomized controlled trial,
73 may represent a valuable addition for the prevention and/or therapeutic management of mild COVID-19
74 ambulatory patients.

75

76 **Material and Methods**

77 ***CAPEo production and use***

78 Spanish oregano (*Coridothymus capitatus* (L) Rchb. F. synonym of *Thymbra capitata* (L) Cav.), dictamnus
79 or Cretan dittany (*Origanum dictamnus* L) and sage (*Salvia fruticosa* Mill., *Salvia pomifera* L., were
80 cultivated under total Good Agricultural Practice and high precision agriculture, based on an Ecological
81 Niche Modelling tool, we have recently developed (Bariotakis et al., 2019), in order to maximize their
82 essential oil composition and content. A constant genotype of plants, specified by a barcoding of each
83 batch, was used. Essential oils were prepared by steam distillation of the dried plant leaves, under GMP
84 conditions. The final extract, contained 4 parts *Corydothymus Capitatus* (L) extract, 2 parts *Salvia Fruticosa*
85 Mill. extract and 1 part *Origanum Dictsmnus* L extract. It was analyzed by Gas Chromatography–Mass
86 Spectroscopy (GC–MS), in a Shimadzu, QP 5050A apparatus. The mixture of essential oils contains
87 carvacrol (53%) eucalyptol (13%) and β -Caryophyllene (3%). Concentrations of the compounds p-Cymene,
88 γ -Terpinene, Borneol and α -Terpineol were 1.32, 1.17, 1.68 and 1.06% respectively, while the
89 concentrations of the remaining 15 compounds were less than 1%. For the complete analysis of
90 compounds, please refer to previous reports (Duijker et al., 2015;Kalyvianaki et al., 2020). These
91 concentrations refer to the stock essential oil mixture, while a concentration of 1.5% in DMSO (Sigma-
92 Aldrich) was used in the present study. This refers to the dilution 1/1, mimicking the suggested daily dose
93 of the CAPEo extract in humans (1 ml of a 1.5% of CAPEo in olive oil, for the management of upper
94 respiratory tract infections (Duijker et al., 2015;Anastasaki et al., 2017)). As the pharmacokinetics and
95 bioavailability of CAPEo are under investigation, we have used bibliography data, suggesting a variable
96 absorption of phenolic compounds ranging from 27 to 0.0006% and a blood recovery $\leq 1\%$ for the majority
97 of compounds (Scalbert et al., 2002;Manach et al., 2005). Therefore, to mimic available concentrations in
98 humans, different dilutions (1:10, 1:100 and 1:1000 of the clinically administered concentration -15 mL
99 extract/L, 1 mL/day-) in DMSO were used in the present study. The same concentrations were used in a
100 previous study, to determine the protective and therapeutic effect of CAPEo in cells infected with other
101 upper respiratory viruses (Tseliou et al., 2019).

102 ***Virus and virus titration***

103 SARS -CoV-2 (isolate 30-287) was obtained through culture in Vero E6 cells, from an infected patient, in
104 Alexandroupolis, Greece. Virus stock was prepared by infecting fully confluent Vero E6 cells in DMEM,
105 10% fetal bovine serum (FBS), with antibiotics at 37°C, 5% CO₂. Four days after inoculation, the
106 supernatant was frozen at -80°C until use. Titration was carried-out in 96 -well plates using Vero E6 cells
107 and TCID₅₀ was calculated according to the method of Reed and Muench (Reed and Muench, 1938). Plates
108 were incubated at 37°C for 4 days, and the cytopathic effect (CPE) was scored by observation under an
109 inverted phase contrast microscope.

110 ***Infections and Treatment***

111 Infections were carried out in 96-well plates, using SARS -CoV-2 (m.o.i. of 0.1) on Vero E6 cells. Cells were
112 treated with different concentrations of CAPEo, as described above, in a volume of 15 μ l, per 150 μ l of

113 medium, for 48h. Cell morphology was observed with phase contrast, in an inverted microscope, to record
114 CPE. Culture supernatants were also collected and analyzed using real-time RT-PCR.

115 ***Real-time RT-PCR***

116 To determine viral load, RNA was extracted from 96-well supernatants (100 µl) using NucleoSpin Dx Virus
117 according to the manufacturer (Macherey Nagel). Multi-target real-time RT-PCR was performed using
118 COVID-19 SARS-Cov-2 Real-TM according to the manufacturer (Sacace Biotechnologies, Como, Italy).

119 ***Patients included in the study***

120 Seventeen (17) young adult patients (34.4±11 years) were included in a Proof-of-Concept intervention
121 study, reporting to a single primary care unit with symptoms, related to an upper respiratory tract
122 infection. SARS-CoV-2 infection was confirmed by real-time PCR, performed in the regional COVID-19
123 reference centre for COVID infections (Laboratory of Clinical Virology, University of Crete, School of
124 Medicine). The study was conducted from Sep 1 to Oct 15, 2020. In parallel to the eligible patients, data
125 for two family members (real-time PCR negative) of one infected participant, were included in the study
126 analysis (see Results). The CAPEo mixture, in the form of two 0.5 ml soft capsules, in a concentration of
127 15 ml/L, was administered daily for two weeks (14 days), *per os*. Information regarding demographics,
128 medical history, smoking habits, symptoms and signs has been recorded in a pre-tested questionnaire for
129 all study participants (Table 1).

130 Data were collected on day 1, day 4, day 7 and day 14; following the initial face-to-face consultation, data
131 collection and consultations were performed, either remotely (by phone), or via home visits, by trained
132 medical personnel. The severity of symptoms was assessed through the utilisation of a seven-point Likert
133 scale, with data recorded on Day 1 and taken as the baseline. A seven-point Likert scale allowed recording
134 of reported symptoms starting from 1 (minor) to 2 (very mild) and 3 (mild), 4 (somewhat moderate) and
135 5 (moderate) and culminating to 6 (severe) and 7 (very severe). The main outcome defined to assess the
136 clinical effectiveness of the CAPEo was symptom reduction, in terms of severity and frequency, defined
137 as total number of symptoms over the 14-day period, and with measurement on day 4, day 7 and day 14.
138 Five patients reported symptoms prior to their confirmed diagnosis; the corresponding interval varied
139 from 2 to 4 days. For the purposes of reporting and given the small interval prior to the confirmed
140 diagnosis and study inclusion, the date of the confirmed diagnosis, i.e., day 1 of the study was considered
141 as day 1 for symptoms, and severity and frequency assessment.

142 ***Statistical analysis***

143 Data were analyzed using the SPSS software (IBM SPSS Statistics for Windows, Version 26.0 Armonk, NY:
144 IBM Corp) and Origin Pro 2018 (Originlab Co, Nothampton, MA). A critical value of 0.05 was
145 taken as the threshold of statistical significance.

146 ***Ethics***

147 The study received approval by the University of Crete Bioethics Committee (No 78/01.04.2020). This
148 study was registered in ClinicalTrials.gov, with number NCT04705753.

150 **Results**

151 ***Protective effect of CAPEo on VERO cells***

152 The potential antiviral effect of CAPEo against SARS-CoV-2 was assessed both at cellular and molecular
153 level, *in vitro*. Cells infected with SARS-CoV-2 present a CPE effect. CPE of infected VERO cells, was
154 monitored in the presence of different concentrations of CAPEo (Figure 1A). As shown, cells were viable
155 and presented a morphology similar to that of non-infected cells, up to a concentration of 1/100 CAPEo,
156 where minimal CPE was present. At lower concentrations, CPE was obvious and cell morphology was more
157 similar to the vehicle (DMSO)-treated cells. Similar results were found in cells preincubated with the same
158 concentrations of CAPEo, for 2h, before infection with SARS-CoV-2 (0.1 m.o.i.).

159 To avoid drug carry-over effects during TCID₅₀ and to assess more accurately viral RNA production, we
160 used quantitative real time PCR for the determination of viral RNA presence in culture medium. Real-time
161 PCR analysis of three different SARS-CoV-2 genes (N, E, and SARS-CoV/SARS-CoV-2 common E region),
162 from the supernatant of infected cells, treated with different concentrations of CAPEo, is shown in Figure
163 1B. Results (expressed as % of non-treated cells) showed that at a concentration of 1/10, CAPEo
164 significantly reduced the viral release to the medium by >80%. The effect, albeit smaller (~35%), persisted
165 at concentrations of CAPEo 1/100 of the suggested dose in humans, but is absent at concentrations
166 1/1000. The calculated IC₅₀ of CAPEo, with a logistic curve fitting, is 1/60 of the proposed dose for viral
167 growth and ~1/250 for maintenance of the cell phenotype. Interestingly, similar results (Figure 1C) were
168 found when VERO cells were preincubated with different concentrations of CAPEo for 2h prior infection,
169 suggesting that CAPEo, in addition to a possible therapeutic action, might be dotted with a prophylactic
170 effect against SARS-CoV-2 virus.

171 ***Effect of a 14-days CAPEo administration in humans on the severity and duration of symptoms of COVID- 172 19-positive individuals. A proof-of-concept study***

173 Results, presented above, suggest a direct SARS-CoV-2 inhibitory effect of CAPEo in cells. In order to
174 provide a proof of concept on the effect of the preparation in humans, we have performed a small
175 intervention study in 17 COVID-19-positive individuals, with mild symptoms, not necessitating
176 hospitalization, in the context of a primary care center. No adverse effects were noted in any patient, in
177 accordance with our previous observations in humans (Duijker et al., 2015;Anastasaki et al., 2017) and
178 experimental animals (Kalyvianaki et al., 2020). The average age of enrolled patients was 34.4±11.0 years
179 and underlying morbidities were reported in 29.4% of them; co-morbidities included dyslipidaemia,
180 obesity, COPD and Hashimoto disease. Based on the questionnaire used, infection source was established
181 to be either cohabitation (23.5%) or close contact with a confirmed case (58.8%).

182 On day 1, these individuals have consulted their General Practitioner (GP), with a variety of symptoms,
183 both general and local (Figure 2A). Interestingly, general symptoms (fever, which in our population was
184 mild, lower than 37.5°C, in all that two individuals, headache, fatigue and myalgias) were similar to those
185 previously reported in two of the largest studies, focusing on symptom duration for COVID-19 outpatients
186 in the US (Tenforde et al., 2020) and on the clinical presentation of mild-to-moderate forms of COVID-19

187 in Europe (Lechien et al., 2020). However, in our group, the frequency of nasal congestion, cough, anosmia
188 and ageusia was lower.

189 In our study group, we have observed that the number of symptoms (4 at day1, 2 at day 4 and 1 at day 7)
190 and the frequency of symptoms significantly decreased after CAPEo administration (Table 2, Figure 2B,
191 left panel). The severity of symptoms, measured as the sum of symptoms in the seven-point Likert scale
192 (see Material and Methods) was also decreased, following CAPEo administration (Wilcoxon tests; $p < 0.01$,
193 Table 2). Interestingly, at day 14, almost all symptoms completely regressed, with the notable exception
194 of anosmia and ageusia, and mild ENT symptoms (nasal congestion and cough, in a small number of
195 patients). EC_{20} , EC_{50} and EC_{80} , calculated with a logistic fit from data shown in Table 2 for the totality of
196 symptom frequency and intensity was 2.3, 3.7 and 5.7 days respectively. Unfortunately, there are not
197 many studies reporting the evolution of COVID-19 symptoms for comparison. From the two large
198 published studies (Allen et al., 2020; Tenforde et al., 2020), we have extracted values from reported
199 figures, with the help of the web resource WebPlotDigitizer (<https://apps.automeris.io/wpd>) (Rohatgi,
200 2020). Data from (Tenforde et al., 2020) are reported in Figure 2B, right panel. Fourteen days after COVID-
201 19 testing, a number of symptoms persist; they include headache, fatigue, myalgias, anosmia, ageusia and
202 respiratory distress. Concerning the common general symptoms (Figure 2C), we observe a notable,
203 significant difference in the frequency of occurrence of headache, fatigue and myalgias, while fever was
204 absent in both groups and a similar proportion of patients with persisting anosmia and ageusia.

205 Symptoms evolution was compared to that reported by (Tenforde et al., 2020); the authors report
206 symptoms at days 1 and 14. In another study, we have used also as reference (Allen et al., 2020), including
207 a much larger number of cases, symptoms were self-reported, daily, but without the implication of a
208 medical examiner. We also used these data for comparison, as the frequency of symptoms was
209 significantly different from the two other studies (Lechien et al., 2020; Tenforde et al., 2020), at day 1. A
210 complete resolution of headache, a major symptom in COVID-19, was found in our group, with $T_{1/2}$ of 5.1
211 days, while it persisted in 14% of cases in (Tenforde et al., 2020) and was almost absent in (Allen et al.,
212 2020). Fatigue was also completely resolved in our group with $T_{1/2}$ of 5.8 days, while it persisted in 35% of
213 patients in the study of (Tenforde et al., 2020) and at about 15% in (Allen et al., 2020). Fever, another
214 major symptom in day 1, completely resolved in our group, with $T_{1/2}$ of 2.7 days, as compared to ~9 days
215 in (Allen et al., 2020). At 14 days, fever was also absent in studies by (Allen et al., 2020; Tenforde et al.,
216 2020). Therefore, CAPEo seems to ameliorate general symptoms very quickly, better than the reference
217 population. In addition, as shown in Figure 2B, the majority of symptoms, both general and local,
218 completely resolve at the end of the first week. A special notion applies to anosmia and ageusia. Both in
219 our group and in the European multi-center study (Allen et al., 2020), these symptoms progressively
220 increase, peaking at day 4 and at days 4-6 respectively. Thereafter, at day 14, these two symptoms persist
221 in 17%, 23% and 21% in our group, in (Tenforde et al., 2020) and in (Allen et al., 2020) studies, respectively.

222 As mentioned, and according to protocol, we included three subjects in the analysis since they were family
223 members (father, mother and sister of one patient), working together and living in the same house. They
224 received the CAPEo for prophylactic use, on the basis of the decision of the family doctor, despite having
225 tested negative for SARS-CoV-2. One of them (mother) presented symptoms two days after the baseline,
226 and was re-tested and found positive, and she was enrolled in the study, while the remaining two (father

227 and sister) did not report symptoms on any of the days of observation. We consider this an important
228 reporting aspect in terms of establishing guidelines for sequential testing, managing oligo- or
229 asymptomatic patients, in outpatient settings and to inform future clinical study design across settings, as
230 highlighted by a recent report (Wernhart et al., 2020). The median incubation period of five days creates
231 a false sense of safety, but also presents a challenge in terms of study inclusion and sound trial conduct
232 and reporting (Lauer et al., 2020).

233

234 Discussion

235 The COVID-19 pandemics imposed a number of, not yet resolved, problems to the International Scientific
236 Community. Thanks to the combined world-wide scientific effort and the analysis of SARS-CoV-2 virus
237 (O'Leary and Ovsepian, 2020), successful and safe vaccines are now begin to emerge (Polack et al.,
238 2020;Voysey et al., 2020). Although multiple molecules are at various stages of preclinical and clinical
239 development, there largely remains an unmet need for prophylactic and therapeutic regimens to combat
240 the disease, with proposed measures being scarce and non-specific (Bolarin et al., 2020;Wang et al.,
241 2020a), with the exception of monoclonal antibodies (Baum et al., 2020;Hansen et al., 2020;Weinreich et
242 al., 2020) and dexamethasone (Cain and Cidlowski, 2020;Recovery Collaborative Group et al., 2020), which
243 primarily target hospitalized patients in intensive care units. In this respect, the need for non-expensive
244 therapeutic regimens, safe and effective in non-critically-ill patients and efficient for their management
245 in ambulatory settings, remain unmet. Accordingly, drug repurposing, for candidates acting against known
246 or predicted SARS-CoV-2 protein actions have been advanced (reviewed and discussed in (Asselah et al.,
247 2020;Cadegiani, 2020;Khan et al., 2020)), while natural products have also been tested (reviewed in
248 (Benarba and Pandiella, 2020)). Finally, quercetin has been proposed as an alternative for dexamethasone
249 (Pawar and Pal, 2020). Here, we suggest CAPEo as a potential novel agent, for the safe and effective
250 therapeutic management of ambulatory mild cases of COVID-19.

251 CAPEo, a 1.5% of essential oils of *Thymbra capitata* (L.) Cav., *Salvia fruticosa* Mill. and *Origanum dictamnus*
252 L. in olive oil, has been advanced by our group in 2015, and found to be effective in reducing the severity
253 and duration of symptoms of viral upper respiratory tract infections (Duijker et al., 2015;Anastasaki et al.,
254 2017). It presents remarkable anti-viral properties against Influenza A and B strains and HRV14 (Tseliou et
255 al., 2019), while it is safe in both experimental animals (Kalyvianaki et al., 2020) and humans (Duijker et
256 al., 2015). Its properties have been recently reviewed in reference (Pirintsos et al., 2020). Here, we extend
257 these previous findings, by providing *in vitro* evidence about its antiviral activity against SARS-CoV-2
258 infected VERO cells. CAPEo was effective at concentrations compatible with the expected circulating
259 concentrations of CAPEo constituents (Scalbert et al., 2002;Manach et al., 2005), and similar with the
260 previously reported *in vitro* antiviral activity in Influenza strains and HRV14 (Tseliou et al., 2019).
261 Interestingly, as shown in Figure 1, CAPEo mixture was both prophylactic and therapeutic *in vitro*, at
262 concentrations up to 1/100 the suggested *per os* dose in humans, preserving the viability, cell phenotype
263 and viral RNA presence in the culture medium. In this respect, calculated EC₅₀ through a logistic fit was
264 estimated as 1/60 of the proposed dose for viral growth, and ~1/250 for cell phenotype, compatible with
265 the expected concentrations of CAPEo constituents in human plasma (Scalbert et al., 2002;Manach et al.,
266 2005).

267 CAPEo contains 25 different micro-constituents (please refer to Supplemental Table 4 of Reference
268 (Duijker et al., 2015), for an exhaustive presentation of concentrations of specific constituents). The main
269 compounds are carvacrol (53%), eucalyptol (13%), β -Caryophyllene (3%), p-Cymene (1.32%), γ -Terpinene
270 (1.17%), Borneol (1.68%) and α -Terpineol (1.06%). As reviewed recently (Pirintsos et al., 2020), none of
271 these compounds have been reported as anti-virals. However, work in progress in our group has identified
272 specific viral targets for some of these constituents, with a direct impact on viral replication.

273 Based on the encouraging *in vitro* results, and having ensured the safety of CAPEo in experimental animals
274 (Kalyvianaki et al., 2020) and humans (Duijker et al., 2015), we have further performed a Proof-of-Concept
275 intervention study in humans. Due to the very low incidence of COVID-19 positive cases in Crete, at the
276 time of the study, only seventeen (17) eligible ambulatory patients, positive for COVID-19 by real-time
277 quantitative PCR, were enrolled, and tested for the severity and duration of general and local symptoms,
278 for 14 days. We have chosen this interval as previous studies report a self-resolution of mild COVID-19
279 cases in 14 (Tenforde et al., 2020), or 14-21 days (Allen et al., 2020) and the persistence of virus in upper
280 respiratory tract samples for about 10 days (Singanayagam et al., 2020). A concrete limitation of this study
281 is that we do not have a control group; we have therefore compared the evolution of disease symptoms
282 with the few studies reporting the evolution of symptoms in non-hospitalized patients (Allen et al.,
283 2020;Tenforde et al., 2020). As discussed previously (Allen et al., 2020;Lechien et al., 2020), symptoms
284 may vary significantly, related to the ethnicity of participants. At the beginning of the study (patient
285 consultation and positive real-time PCR result), the main general symptoms include headache, myalgia,
286 weakness and fever, in accord with previous investigations (Allen et al., 2020;Lechien et al., 2020;Tenforde
287 et al., 2020). However, in our group, fever was low <37.5°C in all but one patient, and the frequency and
288 severity of other symptoms, such as gastrointestinal (diarrhea, respiratory and ENT symptoms were low,
289 possibly because of the low viral load, but without excluding the possibility of simply witnessing an effect
290 prevalent simply because of the small group size.

291 Symptoms evolution was compared to that reported symptoms at days 1 and 14, by (Tenforde et al., 2020)
292 and (Allen et al., 2020), including a larger number of cases, in which symptoms were self-reported, daily,
293 but without the participation of a medical examiner. In our group, treated with CAPEo, we report a
294 complete resolution of headache, fatigue and fever, major general symptoms in COVID-19. In contrast,
295 headache, and fatigue persisted in the studies of (Allen et al., 2020;Tenforde et al., 2020), while fever was
296 equally resolved. We have therefore concluded that CAPEo ameliorates general symptoms very quickly,
297 better than an untreated population. In addition, as shown in Figure 2B, the majority of symptoms, both
298 general and local, almost completely resolve at the end of the first week. Although we have not analyzed
299 in depth the underlying mechanism of action for this beneficial effect of CAPEo in the evolution of COVID-
300 19, in addition to the possible direct anti-viral effect reported in cells, another mechanism of action might
301 be its anti-inflammatory effect, previously reported in experimental animals (Kalyvianaki et al., 2020) and
302 humans (Duijker et al., 2015). Anosmia and ageusia, however, evolved both in our group and in (Allen et
303 al., 2020), presenting a maximum at day 4 and at days 4-6 respectively, and persist in 17%, 23% and 21%
304 in our group, in the study of (Tenforde et al., 2020) and in the population reported by (Allen et al., 2020)
305 respectively. Whether this is due to a late recovery of nasal and buccal mucosa, or in the persistence of
306 virus in a small percentage of patients (Singanayagam et al., 2020) is not clear yet.

307 In conclusion, our findings suggest that CAPEo, a mixture of essential oils of three Cretan aromatic plants,
308 possesses a potent antiviral activity, in addition to Influenza and HRV14 (Tseliou et al., 2019), against SARS-
309 CoV-2, in which it also possesses a prophylactic activity. In addition, our reported here proof-of-concept
310 intervention study in humans shows that it significantly reduces general and local symptoms of mild
311 COVID-19 patients. If these results will be confirmed in a planned prospective clinical study, CAPEo might
312 be a novel, inexpensive, therapeutic agent in cases of ambulatory COVID-19 patients.

313 **Author Contribution**

314 CL conceived the Proof-of-Concept clinical study. GS, IK and EC designed the experimental studies. CL, EP,
315 ES, and ML equally participated in the design of the Proof-of-Concept clinical study and the analysis
316 thereof. EP, AD, and CL were responsible for trial conduct and all clinical operation aspects, including the
317 preliminary trial report, whereas ML and EC performed the statistical analysis. GS performed the COVID-
318 19 real-time quantitative PCR in clinical samples. SAP and MK participating in the design and analysis of
319 experimental data. IK and MP performed the *in vitro* studies and IK drafted the initial report. EC wrote the
320 first draft of the paper, while all authors contributed to the reduction of the manuscript. All authors
321 approved the submission.

322 **Funding**

323 The clinical study, for which the Ethics Approval was given was exclusively supported by Clinic of Social
324 and Family Medicine, University of Crete, funds. The work was also partially supported by Olvos Science
325 SA and a grant from Galenica SA to IK.

326 **Conflict of Interest**

327 SAP, CL and EC are inventors in patents CN102762218, EP2482831 and WO2011045557, with priority
328 numbers WO2010GB01836 20100929 and GB20090017086 20090929, related to the antiviral activity of
329 the CA_{Peo}.

330

331 References

- 332
- 333 Allen, W.E., Altae-Tran, H., Briggs, J., Jin, X., Mcgee, G., Shi, A., Raghavan, R., Kamariza, M., Nova, N.,
334 Pereta, A., Danford, C., Kamel, A., Gothe, P., Milam, E., Aurambault, J., Primke, T., Li, W.,
335 Inkenbrandt, J., Huynh, T., Chen, E., Lee, C., Croatto, M., Bentley, H., Lu, W., Murray, R., Travassos,
336 M., Coull, B.A., Openshaw, J., Greene, C.S., Shalem, O., King, G., Probasco, R., Cheng, D.R.,
337 Silbermann, B., Zhang, F., and Lin, X. (2020). Population-scale longitudinal mapping of COVID-19
338 symptoms, behaviour and testing. *Nat Hum Behav* 4, 972-982.
- 339 Anastasaki, M., Bertias, A., Pirintzos, S.A., Castanas, E., and Lionis, C. (2017). Post-market outcome of an
340 extract of traditional Cretan herbs on upper respiratory tract infections: a pragmatic, prospective
341 observational study. *BMC Complement Altern Med* 17, 466.
- 342 Asselah, T., Durantel, D., Pasmant, E., Lau, G., and Schinazi, R.F. (2020). COVID-19: discovery, diagnostics
343 and drug development. *J Hepatol*.
- 344 Bariotakis, M., Georgescu, L., Laina, D., Oikonomou, I., Ntagounakis, G., Koufaki, M.I., Souma, M.,
345 Choreftakis, M., Zormpa, O.G., Smykal, P., Sourvinos, G., Lionis, C., Castanas, E., Karousou, R., and
346 Pirintzos, S.A. (2019). From wild harvest towards precision agriculture: Use of Ecological Niche
347 Modelling to direct potential cultivation of wild medicinal plants in Crete. *Sci Total Environ* 694,
348 133681.
- 349 Baum, A., Ajithdoss, D., Copin, R., Zhou, A., Lanza, K., Negron, N., Ni, M., Wei, Y., Mohammadi, K., Musser,
350 B., Atwal, G.S., Oyejide, A., Goez-Gazi, Y., Dutton, J., Clemmons, E., Staples, H.M., Bartley, C.,
351 Klaffke, B., Alfson, K., Gazi, M., Gonzalez, O., Dick, E., Jr., Carrion, R., Jr., Pessaint, L., Porto, M.,
352 Cook, A., Brown, R., Ali, V., Greenhouse, J., Taylor, T., Andersen, H., Lewis, M.G., Stahl, N., Murphy,
353 A.J., Yancopoulos, G.D., and Kyratsous, C.A. (2020). REGN-COV2 antibodies prevent and treat
354 SARS-CoV-2 infection in rhesus macaques and hamsters. *Science*.
- 355 Benarba, B., and Pandiella, A. (2020). Medicinal Plants as Sources of Active Molecules Against COVID-19.
356 *Front Pharmacol* 11, 1189.
- 357 Bolarin, J.A., Oluwatoyosi, M.A., Orege, J.I., Ayeni, E.A., Ibrahim, Y.A., Adeyemi, S.B., Tihamiyu, B.B.,
358 Gbadegesin, L.A., Akinyemi, T.O., Odoh, C.K., Umeobi, H.I., and Adeoye, A.B. (2020). Therapeutic
359 drugs for SARS-CoV-2 treatment: Current state and perspective. *Int Immunopharmacol* 90,
360 107228.
- 361 Cadegiani, F.A. (2020). Repurposing existing drugs for COVID-19: an endocrinology perspective. *BMC*
362 *Endocr Disord* 20, 149.
- 363 Cain, D.W., and Cidlowski, J.A. (2020). After 62 years of regulating immunity, dexamethasone meets
364 COVID-19. *Nat Rev Immunol* 20, 587-588.
- 365 Duijker, G., Bertias, A., Symvoulakis, E.K., Moschandreas, J., Malliaraki, N., Derdas, S.P., Tsikalas, G.K.,
366 Katerinopoulos, H.E., Pirintzos, S.A., Sourvinos, G., Castanas, E., and Lionis, C. (2015). Reporting
367 effectiveness of an extract of three traditional Cretan herbs on upper respiratory tract infection:
368 results from a double-blind randomized controlled trial. *J Ethnopharmacol* 163, 157-166.
- 369 Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, Y., Koon, K., Patel,
370 K., Chung, K.M., Hermann, A., Ullman, E., Cruz, J., Rafique, A., Huang, T., Fairhurst, J., Libertiny, C.,
371 Malbec, M., Lee, W.Y., Welsh, R., Farr, G., Pennington, S., Deshpande, D., Cheng, J., Watty, A.,
372 Bouffard, P., Babb, R., Levenkova, N., Chen, C., Zhang, B., Romero Hernandez, A., Saotome, K.,
373 Zhou, Y., Franklin, M., Sivapalasingam, S., Lye, D.C., Weston, S., Logue, J., Haupt, R., Frieman, M.,
374 Chen, G., Olson, W., Murphy, A.J., Stahl, N., Yancopoulos, G.D., and Kyratsous, C.A. (2020). Studies
375 in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* 369,
376 1010-1014.

- 377 Kalyvianaki, K., Malamos, P., Mastrodimou, N., Manoura-Zonou, I., Vamvoukaki, R., Notas, G., Malliaraki,
378 N., Moustou, E., Tzardi, M., Pirintzos, S., Lionis, C., Sourvinos, G., Castanas, E., and Kampa, M.
379 (2020). Toxicity evaluation of an essential oil mixture from the Cretan herbs thyme, Greek sage
380 and Cretan dittany. *NPJ Sci Food* 4, 20.
- 381 Khan, Z., Ghafoor, D., Khan, A., Ualiyeva, D., Khan, S.A., Bilal, H., Khan, B., Khan, A., and Sajjad, W. (2020).
382 Diagnostic approaches and potential therapeutic options for coronavirus disease (COVID-19). *New*
383 *Microbes New Infect*, 100770.
- 384 Lauer, S.A., Grantz, K.H., Bi, Q., Jones, F.K., Zheng, Q., Meredith, H.R., Azman, A.S., Reich, N.G., and Lessler,
385 J. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported
386 Confirmed Cases: Estimation and Application. *Ann Intern Med* 172, 577-582.
- 387 Lechien, J.R., Chiesa-Estomba, C.M., Place, S., Van Laethem, Y., Cabaraux, P., Mat, Q., Huet, K., Plzak, J.,
388 Horoi, M., Hans, S., Rosaria Barillari, M., Cammaroto, G., Fakhry, N., Martiny, D., Ayad, T., Jouffe,
389 L., Hopkins, C., Saussez, S., and Yo-Ifos, C.-T.F.O. (2020). Clinical and epidemiological
390 characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J*
391 *Intern Med* 288, 335-344.
- 392 Manach, C., Williamson, G., Morand, C., Scalbert, A., and Remesy, C. (2005). Bioavailability and bioefficacy
393 of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr* 81, 230S-242S.
- 394 O'leary, V.B., and Ovsepian, S.V. (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
395 *Trends Genet* 36, 892-893.
- 396 Pawar, A., and Pal, A. (2020). Molecular and functional resemblance of dexamethasone and quercetin: A
397 paradigm worth exploring in dexamethasone-nonresponsive COVID-19 patients. *Phytother Res*.
- 398 Pirintzos, S.A., Bariotakis, M., Kampa, M., Sourvinos, G., Lionis, C., and Castanas, E. (2020). The Therapeutic
399 Potential of the Essential Oil of *Thymbra capitata* (L.) Cav., *Origanum dictamnus* L. and *Salvia*
400 *fruticosa* Mill. And a Case of Plant-Based Pharmaceutical Development. *Frontiers in Pharmacology*
401 11, 522213.
- 402 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez Marc, G.,
403 Moreira, E.D., Zerbin, C., Bailey, R., Swanson, K.A., Roychoudhury, S., Koury, K., Li, P., Kalina, W.V.,
404 Cooper, D., Frenck, R.W., Jr., Hammitt, L.L., Tureci, O., Nell, H., Schaefer, A., Unal, S., Tresnan, D.B.,
405 Mather, S., Dormitzer, P.R., Sahin, U., Jansen, K.U., Gruber, W.C., and Group, C.C.T. (2020). Safety
406 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*.
- 407 Recovery Collaborative Group, Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L.,
408 Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., Prudon, B., Green, C., Felton, T., Chadwick,
409 D., Rege, K., Fegan, C., Chappell, L.C., Faust, S.N., Jaki, T., Jeffery, K., Montgomery, A., Rowan, K.,
410 Juszczak, E., Baillie, J.K., Haynes, R., and Landray, M.J. (2020). Dexamethasone in Hospitalized
411 Patients with Covid-19 - Preliminary Report. *N Engl J Med*.
- 412 Reed, L.J., and Muench, H. (1938). A simple method of estimating fifty per cent endpoints. *Am. J.*
413 *Epidemiol.* 27, 493-497.
- 414 Rohatgi, A. (2020). *WebPlotDigitizer* [Online]. Pacifica, California, USA: Automeris.io. Available:
415 <https://automeris.io/WebPlotDigitizer> [Accessed].
- 416 Scalbert, A., Morand, C., Manach, C., and Remesy, C. (2002). Absorption and metabolism of polyphenols
417 in the gut and impact on health. *Biomed Pharmacother* 56, 276-282.
- 418 Singanayagam, A., Patel, M., Charlett, A., Lopez Bernal, J., Saliba, V., Ellis, J., Ladhani, S., Zambon, M., and
419 Gopal, R. (2020). Duration of infectiousness and correlation with RT-PCR cycle threshold values in
420 cases of COVID-19, England, January to May 2020. *Euro Surveill* 25.
- 421 Tenforde, M.W., Kim, S.S., Lindsell, C.J., Billig Rose, E., Shapiro, N.I., Files, D.C., Gibbs, K.W., Erickson, H.L.,
422 Steingrub, J.S., Smithline, H.A., Gong, M.N., Aboodi, M.S., Exline, M.C., Henning, D.J., Wilson, J.G.,
423 Khan, A., Qadir, N., Brown, S.M., Peltan, I.D., Rice, T.W., Hager, D.N., Ginde, A.A., Stubblefield,
424 W.B., Patel, M.M., Self, W.H., Feldstein, L.R., Investigators, I.V.Y.N., Team, C.C.-R., and

- 425 Investigators, I.V.Y.N. (2020). Symptom Duration and Risk Factors for Delayed Return to Usual
426 Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United
427 States, March-June 2020. *MMWR Morb Mortal Wkly Rep* 69, 993-998.
- 428 Tseliou, M., Pirintsos, S.A., Lionis, C., Castanas, E., and Sourvinos, G. (2019). Antiviral effect of an essential
429 oil combination derived from three aromatic plants (*Coridothymus capitatus* (L.) Rchb. f.,
430 *Origanum dictamnus* L. and *Salvia fruticosa* Mill.) against viruses causing infections of the upper
431 respiratory tract. *Journal of Herbal Medicine* 17-18.
- 432 Voysey, M., Clemens, S.a.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., Angus, B., Baillie, V.L.,
433 Barnabas, S.L., Bhorat, Q.E., Bibi, S., Briner, C., Cicconi, P., Collins, A.M., Colin-Jones, R., Cutland,
434 C.L., Darton, T.C., Dheda, K., Duncan, C.J.A., Emary, K.R.W., Ewer, K.J., Fairlie, L., Faust, S.N., Feng,
435 S., Ferreira, D.M., Finn, A., Goodman, A.L., Green, C.M., Green, C.A., Heath, P.T., Hill, C., Hill, H.,
436 Hirsch, I., Hodgson, S.H.C., Izu, A., Jackson, S., Jenkin, D., Joe, C.C.D., Kerridge, S., Koen, A., Kwatra,
437 G., Lazarus, R., Lawrie, A.M., Lelliott, A., Libri, V., Lillie, P.J., Mallory, R., Mendes, A.V.A., Milan,
438 E.P., Minassian, A.M., Mcgregor, A., Morrison, H., Mujadidi, Y.F., Nana, A., O'reilly, P.J.,
439 Padayachee, S.D., Pittella, A., Plested, E., Pollock, K.M., Ramasamy, M.N., Rhead, S., Schwarzbold,
440 A.V., Singh, N., Smith, A., Song, R., Snape, M.D., Sprinz, E., Sutherland, R.K., Tarrant, R., Thomson,
441 E.C., Torok, M.E., Toshner, M., Turner, D.P.J., Vekemans, J., Villafana, T.L., Watson, M.E.E.,
442 Williams, C.J., Douglas, A.D., Hill, A.V.S., Lambe, T., Gilbert, S.C., Pollard, A.J., and Oxford, C.V.T.G.
443 (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an
444 interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*.
- 445 Wang, M.Y., Zhao, R., Gao, L.J., Gao, X.F., Wang, D.P., and Cao, J.M. (2020a). SARS-CoV-2: Structure,
446 Biology, and Structure-Based Therapeutics Development. *Front Cell Infect Microbiol* 10, 587269.
- 447 Wang, Y., Huo, P., Dai, R., Lv, X., Yuan, S., Zhang, Y., Guo, Y., Li, R., Yu, Q., and Zhu, K. (2020b). Convalescent
448 plasma may be a possible treatment for COVID-19: A systematic review. *Int Immunopharmacol*
449 91, 107262.
- 450 Weinreich, D.M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B.J., Soo, Y., Rofail, D.,
451 Im, J., Perry, C., Pan, C., Hosain, R., Mahmood, A., Davis, J.D., Turner, K.C., Hooper, A.T., Hamilton,
452 J.D., Baum, A., Kyratsous, C.A., Kim, Y., Cook, A., Kampman, W., Kohli, A., Sachdeva, Y., Graber, X.,
453 Kowal, B., Dicioccio, T., Stahl, N., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G.D., and
454 Trial, I. (2020). REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl*
455 *J Med*.
- 456 Wernhart, S., Forster, T.H., and Weihe, E. (2020). Outpatient Management of Oligosymptomatic Patients
457 with respiratory infection in the era of SARS-CoV-2: Experience from rural German general
458 practitioners. *BMC Infect Dis* 20, 811.
- 459

460 **Tables and Figures**

461 **Table 1**

462 Descriptive characteristics of the 17 patients included in the study

		n	%
Gender	<i>men</i>	8	47.1
	<i>women</i>	9	52.9
Age (years)	<i>Average age ± S.D. (min, max)</i>	34.4±11.0	
Nationality	<i>Greek</i>	16	94.2
Smokers	<i>current</i>	3	17.6
	<i>former</i>	4	23.5
Morbidity	<i>yes^a</i>	5	29.4
Cohabitation with a COVID-19 patient	<i>yes</i>	4	23.5
Close contact with a confirmed case	<i>yes</i>	10	58.8
Symptom manifestation prior or upon inclusion in the study	<i>yes^b</i>	15	88.2
Testing for preventive purposes	<i>yes^b</i>	3	17.6
Administration/intake of medicinal or other compound for the symptoms before, at the point of or following inclusion to the study (additionally to CAPEo)	<i>yes</i>	8	47.1
	<i>painkillers</i>	5	29.4
	<i>antibiotics</i>	4	23.5
	<i>probiotics, oestrogens</i>	2	11.8

^a Pertains to dyslipidaemia, obesity, COPD and Hashimoto disease.

^b Information from the document accompanying the clinical sample for laboratory testing and regulating issues by the National Organization for Public Health (EODY).

463

464

465 **Table 2**

466 Change of total number of symptoms recorded on Day 1, 4, 7 and 14.

467

		Consultation Day Recording				
		1	4	7	14	p-value
Number of symptoms		75	38	18	8	
Δ -change (%)	1st → 4th		-37 (-49.3%)			0.009
	1st → 7th			-57 (-76.0%)		<0.001
	1st → 14th				-67 (-89.3%)	<0.001
	4th → 7th			-20 (-52.6%)		0.004
Wilcoxon tests (Monte Carlo simulation)						

468

469




470 **Figure 1**




471 *In vitro* effect of CAPEo on SARS-Cov2 induced CPE and SARS-Cov2 replication. **A.** Light microscopy
472 photographs of CPE in control (0, DMSO) and SARS-CoV-2 infected VERO cells (0.1 m.o.i), pre-treated or
473 co-treated with different concentrations of CAPEo, in DMSO. **B.** Bar chart representing relative abundance
474 (% of untreated control) of SARS-Cov2 RNA after pre-treatment (B) or co-treatment (C) with different
475 concentrations of CAPEo, using real-time quantitative RT-PCR, targeting N and E regions of SARS-Cov2
476 genome and E-common region shared by SARS-CoV and SARS-CoV-2 viruses.

477 **Figure 2**

478 CAPEo administration in humans ameliorates symptoms of mild COVID-19 in ambulatory patients. **A.**
479 Frequency of symptoms, common to both studies at Day 1, in our group and in (Tenforde et al., 2020). **B.**
480 Heatmaps of symptom frequency in our CAPEo-treated group (left panel) and the population reported by
481 (Tenforde et al., 2020) (right panel). **C.** Evolution of selected symptoms in our CAPEo-treated group (red
482 curves). $T_{1/2}$ for the resolution of symptoms was calculated with a logistic regression fit, with Origin Pro
483 2018. For comparison, the frequency of symptoms in the reference population reported by (Tenforde et
484 al., 2020) is also presented (green curves). In panels B-C, the frequency of symptoms was extracted from
485 Figure 1 of (Tenforde et al., 2020), with the online resource WebPlotDigitizer (Rohatgi, 2020).

486



A**B****Legend****C**